India bans manufacture and sale of oral nimesulide above 100 mg
Change
India's government banned all oral nimesulide formulations above 100 mg due to health risks, following ICMR's recommendation.
Why it matters
The Indian government prohibited the manufacture, sale, and distribution of all oral formulations of nimesulide above 100 mg for human use. This decision was based on findings by the Indian Council of Medical Research that highlighted serious health risks, especially for children under 18 and elderly people over 60. The ban replaces previous restrictions targeting pediatric and veterinary use and affects a market worth Rs 497 crore. The ban matters as it aims to reduce adverse reactions and protect public health by promoting safer alternatives.
Implications
Unlock the decision layer.
Know what's at risk and what to do next.
- Implications: What this forces you to change — operations, exposure, or compliance.
- Who is affected: Which roles, contracts, and obligations are exposed.
- What to watch: Binding deadlines and enforcement dates.
- Real-time alerts: Delivered the moment a binding change is published.
- Ask AI: Ask what this means for your specific role.
No credit card · 14-day trial · Active in seconds
Unlock the decision layer